Skip to content

Clinical Study for Thermal Ablation Under Medical Thoracoscopic Guidance in the Treatment of Pleural Metastases

Clinical Study for Thermal Ablation Under Medical Thoracoscopic Guidance in the Treatment of Pleural Metastases

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020984
Enrollment
Unknown
Registered
2019-01-23
Start date
2019-10-01
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pleural Metastases

Interventions

Group A :Argon Knife Guided by Video-Assisted Thoracoscopic Surgery
Group B:Closed Thoracic Drainage and Intracavitary Injection of Nedaplatin
Group C:Intrapleural Injection of Nedaplatin after Thermal Ablation under Video-Assisted Thoracoscopic Guidance

Sponsors

Integrated Hospital of Traditional Chinese Medicine, Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with malignant tumor; 2) Patients with pleural metastasis is required if there is no diagnosis of malignancy; 3) Patients with malignant pleural effusion; 4) Aged between 18 and 70 year old male and female; 5) Physical condition Karnofsky score greater than 60; 6) Without severe complications; 7) Patients who are able to read Chinese and willingness to provide signed informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with extensive pleural adhesion; 2) Patients with severe cough or severe debilitation who are unable to undergo surgery; 3) Patients with severe heart disease, arrhythmia or cardiac insufficiency; 4) Patients with severe pulmonary accompanied by dyspnea and are unable to lie flat; 5) Patients with severe pulmonary hypertension(=4.67Kpa); 6) Patients with coagulation disorder or the count of blood platelet is less than 40×10^9/L or the prothrombin time below 40%; 7) Patients with cachexy who are unable to receive medical thoracoscopic treatment; 8) Pregnant women; 9) Patients get involved in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Number of pleural metastases;Size of pleural metastases;Growth rate of malignant pleural effusion;

Secondary

MeasureTime frame
The improvement of symptoms includes Chest tightness, shortness of breath, dyspnea, chest pain and so on;Complications;Placing time and discharge of thoracic duct;Peri-treatment infection rate;Quality of life questionnair scorese;Karnofsky questionnair scorese;Survival frequency;Cost;

Countries

China

Contacts

Public ContactQixiao Feng

Integrated Hospital of Traditional Chinese Medicine, Southern Medical University

cxhfqx@163.com+86 18520088212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026